+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biomarker Technologies Market by Product, Technology and Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4828587
  • Report
  • Region: Global
  • 255 pages
  • Allied Analytics LLP
1 of 5
The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.

Biomarker is a biological marker, which indicates a substance or a physical event. These indicated substances or events can be measured and the measurements can be further used for the detection of diseases, a physiological change, response to a treatment and a psychological condition. Biomarker technologies are different techniques, which are employed for testing various diseases. These technologies employ the use of different products to measure a biomarker. Reagents and assays are used in various biomarker technologies such as next generation sequencing, polymerase chain reaction, and others. These biomarker technologies are used in various fields of science such as drug discovery, diagnostics, and personalized medicine. Majorly biomarkers are used to detect diseases such as cancer, infectious diseases, autoimmune diseases, neurological disorders, and others.

Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market. The rise in awareness toward the need of early detection of various diseases such as cancers and high growth potential in emerging economies is anticipated to provide lucrative opportunities in the market during the forecast period. However, high initial investment required for biomarker discovery restricts the growth of the biomarker technologies market.

The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product, the market is divided into consumables, and instruments. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. On the basis of application, the market is classified into drug discovery, diagnostics and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global biomarker technologies market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2018 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of biomarker technologies such as polymerase chain reaction, next generation sequencing, immunoassay and others is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Product
  • Consumables
o Assay
o Reagent
  • Instruments
By Technology
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Immunoassay
  • Others
By Application
  • Drug Discovery
  • Diagnostics
  • Personalized Medicine
By Indication
  • Cancer
  • Infectious Diseases
  • Autoimmune Disorders
  • Cardiovascular Disorders
  • Others
By Region
  • North America
o U.S.
o Canada
o Mexico
  • Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
  • Asia-Pacific
o India
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
  • LAMEA
o Brazil
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • LI-COR, Inc.
  • Merck KGAA
  • PERKINELMER INC.
  • QIAGEN
  • Shimadzu Corporation
  • Thermo Fisher Scientific, Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Eurofins Scientific
  • Enzo Biochem, Inc.
  • EKF Diagnostics Holdings plc
  • Myriad Genetics, Inc. (Myriad RBM.).
  • Becton, Dickinson and Company
Note: Product cover images may vary from those shown
2 of 5
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. Key findings
2.2.1. Top impacting factors
2.2.2. Top investment pockets
2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Forces Shaping Biomarker technologies Industry/Market
3.2.1. Moderate bargaining power of supplier
3.2.2. Low bargaining power of buyers
3.2.3. Low threat of substitutes
3.2.4. High intensity of rivalry
3.2.5. Low threat of new entrant
3.3. Pricing Analysis
3.3.1. Pricing Analysis of Biomarker technologies, By Region, 2018 & 2025
3.4. Market evolution/Industry roadmap
3.5. Value Chain Analysis
3.6. Impact of government regulations on global biomarker technologies market
3.7. Industry Pain point analysis
3.8. Market dynamics
3.8.1. Drivers
3.8.1.1. Rise in prevalence of various diseases
3.8.1.2. Surge in R&D activities in healthcare coupled with rise in adoption of early toxicity testing
3.8.1.3. Advantages offered by biomarker in drug development
3.8.1.4. Increase in genome mapping programs
3.8.2. Restraints
3.8.2.1. High initial capital investments required for biomarker discovery
3.8.2.2. Lack of awareness regarding the use of biomarker technologies
3.8.3. Opportunity
3.8.3.1. High potential of the emerging economies
3.8.4. Impact Analyses

CHAPTER 4: BIOMARKER TECHNOLOGIES MARKET, BY PRODUCT AND SERVICES
4.1. Overview
4.2. Consumables
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Reagents
4.2.2.1.1. Market size and forecast
4.2.2.2. Assays
4.2.2.2.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis by country
4.3. Instruments
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country

CHAPTER 5: BIOMARKER TECHNOLOGIES MARKET, BY TECHNOLOGY
5.1. Overview
5.2. Polymerase Chain Reaction (PCR)
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Next Generation Sequencing (NGS)
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Immunoassay
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis by country

CHAPTER 6: BIOMARKER TECHNOLOGIES MARKET, BY APPLICATION
6.1. Overview
6.2. Drug Discovery
6.2.1. Market size and forecast, by region
6.2.2. Market analysis by country
6.3. Diagnostics
6.3.1. Market size and forecast, by region
6.3.2. Market analysis by country
6.4. Personalized Medicine
6.4.1. Market size and forecast, by region
6.4.2. Market analysis by country

CHAPTER 7: BIOMARKER TECHNOLOGIES MARKET, BY INDICATION
7.1. Overview
7.2. Cancer
7.2.1. Market size and forecast, by region
7.2.2. Market analysis by country
7.3. Infectious Diseases
7.3.1. Market size and forecast, by region
7.3.2. Market analysis by country
7.4. Autoimmune Disorders
7.4.1. Market size and forecast, by region
7.4.2. Market analysis by country
7.5. Cardiovascular Disorders
7.5.1. Market size and forecast, by region
7.5.2. Market analysis by country
7.6. Others
7.6.1. Market size and forecast, by region
7.6.2. Market analysis by country

CHAPTER 8: BIOMARKER TECHNOLOGIES MARKET, BY REGION
8.1. Overview
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. Market analysis by country
8.2.2.1. U.S.
8.2.2.1.1. U.S. market size and forecast, by product and services
8.2.2.1.2. U.S. market size and forecast, by technology
8.2.2.1.3. U.S. market size and forecast, by application
8.2.2.1.4. U.S. market size and forecast, by indication
8.2.2.2. Canada
8.2.2.2.1. Canada market size and forecast, by product and services
8.2.2.2.2. Canada market size and forecast, by technology
8.2.2.2.3. Canada market size and forecast, by application
8.2.2.2.4. Canada market size and forecast, by indication
8.2.2.3. Mexico
8.2.2.3.1. Mexico market size and forecast, by product and services
8.2.2.3.2. Mexico market size and forecast, by technology
8.2.2.3.3. Mexico market size and forecast, by application
8.2.2.3.4. Mexico market size and forecast, by indication
8.2.3. North America market size and forecast, by product and services
8.2.4. North America market size and forecast, by technology
8.2.5. North America market size and forecast, by application
8.2.6. North America market size and forecast, by indication
8.3. Europe
8.3.1. Key market trends and opportunities
8.3.2. Market analysis by country
8.3.2.1. Germany
8.3.2.1.1. Germany market size and forecast, by product and services
8.3.2.1.2. Germany market size and forecast, by technology
8.3.2.1.3. Germany market size and forecast, by application
8.3.2.1.4. Germany market size and forecast, by indication
8.3.2.2. France
8.3.2.2.1. France market size and forecast, by product and services
8.3.2.2.2. France market size and forecast, by technology
8.3.2.2.3. France market size and forecast, by application
8.3.2.2.4. France market size and forecast, by indication
8.3.2.3. UK
8.3.2.3.1. UK market size and forecast, by product and services
8.3.2.3.2. UK market size and forecast, by technology
8.3.2.3.3. UK market size and forecast, by application
8.3.2.3.4. UK market size and forecast, by indication
8.3.2.4. Italy
8.3.2.4.1. Italy market size and forecast, by product and services
8.3.2.4.2. Italy market size and forecast, by technology
8.3.2.4.3. Italy market size and forecast, by application
8.3.2.4.4. Italy market size and forecast, by indication
8.3.2.5. Spain
8.3.2.5.1. Spain market size and forecast, by product and services
8.3.2.5.2. Spain market size and forecast, by technology
8.3.2.5.3. Spain market size and forecast, by application
8.3.2.5.4. Spain market size and forecast, by indication
8.3.2.6. Rest of Europe
8.3.2.6.1. Rest of Europe market size and forecast, by product and services
8.3.2.6.2. Rest of Europe market size and forecast, by technology
8.3.2.6.3. Rest of Europe market size and forecast, by application
8.3.2.6.4. Rest of Europe market size and forecast, by indication
8.3.3. Europe market size and forecast, by product and services
8.3.4. Europe market size and forecast, by technology
8.3.5. Europe market size and forecast, by application
8.3.6. Europe market size and forecast, by indication
8.4. Asia-Pacific
8.4.1. Key market trends and opportunities
8.4.2. Market analysis by country
8.4.2.1. Japan
8.4.2.1.1. Japan market size and forecast, by product and services
8.4.2.1.2. Japan market size and forecast, by technology
8.4.2.1.3. Japan market size and forecast, by application
8.4.2.1.4. Japan market size and forecast, by indication
8.4.2.2. China
8.4.2.2.1. China market size and forecast, by product and services
8.4.2.2.2. China market size and forecast, by technology
8.4.2.2.3. China market size and forecast, by application
8.4.2.2.4. China market size and forecast, by indication
8.4.2.3. Australia
8.4.2.3.1. Australia market size and forecast, by product and services
8.4.2.3.2. Australia market size and forecast, by technology
8.4.2.3.3. Australia market size and forecast, by application
8.4.2.3.4. Australia market size and forecast, by indication
8.4.2.4. India
8.4.2.4.1. India market size and forecast, by product and services
8.4.2.4.2. India market size and forecast, by technology
8.4.2.4.3. India market size and forecast, by application
8.4.2.4.4. India market size and forecast, by indication
8.4.2.5. South Korea
8.4.2.5.1. South Korea market size and forecast, by product and services
8.4.2.5.2. South Korea market size and forecast, by technology
8.4.2.5.3. South Korea market size and forecast, by application
8.4.2.5.4. South Korea market size and forecast, by indication
8.4.2.6. Rest of Asia-Pacific
8.4.2.6.1. Rest of Asia-Pacific market size and forecast, by product and services
8.4.2.6.2. Rest of Asia-Pacific market size and forecast, by technology
8.4.2.6.3. Rest of Asia-Pacific market size and forecast, by application
8.4.2.6.4. Rest of Asia-Pacific market size and forecast, by indication
8.4.3. Asia-Pacific market size and forecast, by product and services
8.4.4. Asia-Pacific market size and forecast, by technology
8.4.5. Asia-Pacific market size and forecast, by application
8.4.6. Asia-Pacific market size and forecast, by indication
8.5. LAMEA
8.5.1. Key market trends and opportunities
8.5.2. Market analysis by country
8.5.2.1. Brazil
8.5.2.1.1. Brazil market size and forecast, by product and services
8.5.2.1.2. Brazil market size and forecast, by technology
8.5.2.1.3. Brazil market size and forecast, by application
8.5.2.1.4. Brazil market size and forecast, by indication
8.5.2.2. Saudi Arabia
8.5.2.2.1. Saudi Arabia market size and forecast, by product and services
8.5.2.2.2. Saudi Arabia market size and forecast, by technology
8.5.2.2.3. Saudi Arabia market size and forecast, by application
8.5.2.2.4. Saudi Arabia market size and forecast, by indication
8.5.2.3. South Africa
8.5.2.3.1. South Africa market size and forecast, by product and services
8.5.2.3.2. South Africa market size and forecast, by technology
8.5.2.3.3. South Africa market size and forecast, by application
8.5.2.3.4. South Africa market size and forecast, by indication
8.5.2.4. Rest of LAMEA
8.5.2.4.1. Rest of LAMEA market size and forecast, by product and services
8.5.2.4.2. Rest of LAMEA market size and forecast, by technology
8.5.2.4.3. Rest of LAMEA market size and forecast, by application
8.5.2.4.4. Rest of LAMEA market size and forecast, by indication
8.5.3. LAMEA market size and forecast, by product and services
8.5.4. LAMEA market size and forecast, by technology
8.5.5. LAMEA market size and forecast, by application
8.5.6. LAMEA market size and forecast, by indication

CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. INTRODUCTION
9.1.1. MARKET PLAYER POSITIONING, 2018
9.2. MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018 (%)
9.3. TOP WINNING STRATEGIES
9.4. COMPETITIVE DASHBOARD
9.5. COMPETITIVE HEATMAP

CHAPTER 10: COMPANY PROFILES: BIOMARKER TECHNOLOGIES MARKET
10.1. AGILENT TECHNOLOGIES, INC.
10.1.1. Company overview
10.1.2. Company snapshot
10.1.3. Operating business segments
10.1.4. Product type Portfolio
10.1.5. Business performance
10.2. BIO-RAD LABORATORIES, INC.
10.2.1. Company overview
10.2.2. Company snapshot
10.2.3. Operating business segments
10.2.4. Product type Portfolio
10.2.5. Business performance
10.2.6. Key strategic moves and developments
10.3. F. HOFFMANN-LA ROCHE LTD.
10.3.1. Company overview
10.3.2. Company snapshot
10.3.3. Operating business segments
10.3.4. Product portfolio
10.3.5. Business performance
10.3.6. Key strategic moves and developments
10.4. Illumina, Inc.
10.4.1. Company overview
10.4.2. Company snapshot
10.4.3. Operating business segments
10.4.4. Product Portfolio
10.4.5. Business performance
10.5. LI-COR, Inc.
10.5.1. Company overview
10.5.2. Company snapshot
10.5.3. Operating business segments
10.5.4. Product portfolio
10.6. Merck KGAA
10.6.1. Company overview
10.6.2. Company snapshot
10.6.3. Operating business segments
10.6.4. Product portfolio
10.6.5. Business performance
10.6.6. Key strategic moves and developments
10.7. PERKINELMER INC.
10.7.1. Company overview
10.7.2. Company snapshot
10.7.3. Operating business segments
10.7.4. Product Portfolio
10.7.5. Business performance
10.8. QIAGEN N.V.
10.8.1. Company overview
10.8.2. Company snapshot
10.8.3. Product type portfolio
10.8.4. Business performance
10.9. Shimadzu Corporation
10.9.1. Company overview
10.9.2. Company snapshot
10.9.3. Operating business segments
10.9.4. Product portfolio
10.9.5. Business performance
10.11. Thermo Fisher Scientific, Inc.
10.11.1. Company overview
10.11.2. Company snapshot
10.11.3. Operating business segments
10.11.4. Product Portfolio
10.11.5. Business performance
10.12. Other Key Player Profile
10.12.1. Key player snapshot

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
According to this report titled, 'Biomarker Technologies Market by Product, Technology, Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2019 - 2026,' the biomarker technologies market accounted for $21,594 million in 2018 is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.

Biomarker technologies are techniques that are used to find out biomarkers. These biomarkers are characteristics, genes, or molecules which are used to measure the biological parameters of the body. These biological parameters help in identification of various diseases and can also be helpful in drug discovery. Different technologies, which are used for the identification of biomarkers include next generation sequencing, polymerase chain reactions, immunoassays, and others. These techniques are utilized in various field of science and are mostly used in identification of different disease such as cancers, autoimmune diseases, infectious diseases, and others. Moreover, the use of biomarkers has revolutionized patient treatment, which has become more personalized leading to better treatment outcomes.

The key factors that drive the growth of the global biomarker technologies market are rise in prevalence of various diseases such as cancer, autoimmune diseases, and others. The other factors that contribute toward the growth of the market include surge in research related to drug discovery and increase in healthcare expenditure. However, high initial investments for the discovery of biomarker can hamper the market growth to a certain extent. Whereas, surge in awareness associated with the need of early detection of various diseases such as cancers and high growth potential in emerging economies are anticipated to provide lucrative opportunities in the market during the forecast period.

On the basis of technology, the immunoassay segment was a major revenue contributor in 2018 and is expected to maintain its dominant position throughout the analysis period due to surge in prevalence of various diseases across the globe. For instance, the rise in prevalence of cancer contributes to the growth of biomarker technologies market as biomarkers serve as tools in diagnosis of cancer. Moreover, other diseases such as diabetes type 1, is highly prevalent worldwide. This factor contributes toward the growth of the biomarker technologies market. In addition, infectious diseases such as AIDS, tuberculosis, and others are also diagnosed using biomarkers. Therefore, the factors above mentioned are responsible for the growth of this segment. On the other side, next generation sequencing is expected to be the fastest growing segment during the forecast period as this technique is highly advantageous due to its property of differentiating between closely related tumor cells to provide better understanding of the growth of cancer. Moreover, the rise in research related to cancer worldwide is another factor that boosts the growth of this market.

According to product, the consumables segment accounted for the highest market share in 2018, and is anticipated to maintain this trend during the forecast period, as consumables form an important part of biomarker testing. Instrument segment is the fastest growing segment during the forecast period owing to the technological advancements.

In 2018, North America accounted for the major share of biomarker technologies market size and is expected to continue this trend owing to higher number of R&D activities, presence of skilled technicians, and wide availability of technologically advanced biomarker testing instruments and high prevalence of disease such as cancer, infectious diseases, neurological disorders, autoimmune diseases, and others. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period.

Key Findings of the Biomarker Technologies Market:

Consumables occupied two-third share of the market in 2018.
The next generation sequencing segment is anticipated to grow with the highest CAGR throughout the forecast period.
The drug discovery segment accounted for half share of the global biomarker technologies market in 2018.
The cardiovascular disorders segment is anticipated to grow at the highest rate during the analysis period.

The major companies profiled in this report include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., LI-COR, Inc., Merck KGAA, PerkinElmer Inc., QIAGEN, Shimadzu Corporation, and Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
5 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll